Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women

Drug Metabolism and Disposition

Volumn 26, Issue 7, 1998, Pages 617-622

  Allard, Stéphane ^a   Sainati, Stephen ^b   Roth Schechter, Barbara ^b   Macintyre, John ^b  

^a Lorex Pharmaceuticals   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; NORFLUOXETINE; ZOLPIDEM;

ADULT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BRUXISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; ERYTHEMA MULTIFORME; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; NEUROLOGIC DISEASE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; TASK PERFORMANCE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DRUG INTERACTIONS; FEMALE; FLUOXETINE; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; PYRIDINES; SEX FACTORS;

EID: 0031868906     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. American College of Obstetrics and Gynecology (1993) ACOG technical bulletin 182: depression in women. Int J Gynecol Obstet 43:203-211.
2. Bianchetti G, Dubruc C, Thiercelin JF, et al. (1988) Clinical pharmacokinetics of zolpidem in various physiological and pathological conditions, in Imidazopyridines in Sleep Disorders (Sauvanet JP, Langer SZ and Morselli PL eds) pp 155-164, Raven Press, New York.
3. Boyer WF and Feighner JP (1991) The efficacy of selective serotonin reuptake inhibitors in depression, in Selective Serotonin Uptake Inhibitors (Feighner JP and Boyer WF eds) pp 89-108, Wiley, Chichester, UK.
4. Cavanaugh J, Schneck D and Eason C (1994) Lack of effect of fluoxetine on the pharmacokinetics and pharmacodynamics of estazolam. Clin Pharmacol Ther 55:141.
5. Cook MD and Conner J (1995) Retrospective review of hypnotic use in combination with fluoxetine and sertraline. Clin Drug Invest 9:212-216.
6. De Vane CL (1992) Pharmacokinetics of selective serotonin reuptake inhibitors. J Clin Psychiatry 53(Suppl 2):13-20.
7. Elko CJ, Burgess JL and Robertson WO (1996) Zolpidem (Ambien®) and serotonin reuptake inhibition: possible interaction. North American Congress of Clinical Toxicology Abstr 566.
8. Fleishaker JC and Hulst LK (1991) Pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berlin) 104: 323-327.
9. Freeman H, Puech AJ and Roth T eds (1996) Zolpidem: An Update of Its Pharmacological Properties and Therapeutic Place in the Management of Insomnia. Elsevier, Paris.
10. Gillin JC, Rapaport M, Erman MK, Winokur A and Albala BJ (1997) A comparison of nefazodone and fluoxetine on mood and on objective, subjective and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 58:185-192.
11. Goodwin GM (1996) How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 57(Suppl 4):9-13.
12. Harvent C, Hulhoven R, Desager J, Coupez JM, Guillet PH, Fuseau E, Lambert D and Warrington SJ (1988) Drug interactions investigated with zoipidem, in Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach (Sauvanet JP, Langer SZ and Morselli PL eds) pp 165-173, Raven Press, New York.
13. Lane RM (1996) Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int J Clin Psychopharmacol 11(Suppl 5):31-61.
14. Lemberger L, Rowe H, Bosonworth JC, Tenbarge JB and Bergstrom RF (1988) The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 43:412-419.
15. Mendelson WB (1990) Hypnotics in the treatment of chronic insomnia, in Handbook of Sleep Disorders (Thorpy MG ed) pp 737-753, Marcel Dekker, New York.
16. Neylan CN (1995) Treatment of sleep disturbances in depressed patients. J Clin Psychiatry 56(Suppl 2):56-61.
17. Medical Economics Company (1997) Ambien labeling, in Physicians' Desk Reference, p 2F10, Oradell, NJ.
18. Pichard L, Gillet G, Bonfils C, Domergue J, Thénot J-P and Maurel P (1995) Oxidative metabolism of zolpidem by human liver cytochrome P450s. Drug Metab Dispos 23:1253-1262.
19. Piergies AA, Roth-Schechter B, Shinleber P, McGarry L and Allard S (1996) Pharmacokinetic and pharmacodynamic interaction of zolpidem and fluoxetine. Int J Clin Pharmacol Ther 34:178-183.
20. Preskorn SH (1997) Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32(Suppl 1):1-21.
21. Riesenman C (1995) Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. Pharmacotherapy 15:84S-99S.
22. Roehrs T, Kribbs N, Zorick F and Roth T (1986) Hypnotic residual effects of benzodiazepines with repeated administration. Sleep 92:309-316.
23. Roth T, Hauri P, Zorick F, Sateia M, Roehrs T and Kipp J (1985) The effect of midazolam and temazepam on sleep and performance when administered in the middle of the night. J Clin Psychopharmacol 5:66-69.
24. Roth T, Roehrs TA, Vogel GW and Dement WC (1994) Evaluation of hypnotic medications, in Clinical Evaluations of Psychotropic Drugs: Principles and Guidelines (Prien RF and Robinson DS eds) p 579, Raven Press, New York.
25. Thase ME, Blomgren SL, Birkett MA, Apter JT and Tepner RG (1997) Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 58:16-21.
26. Thase ME and Kupfer DJ (1996) Recent developments in the pharmacotherapy of mood disorders. J Consult Clin Psychol 64:646-659.
27. Thénot JP, Hermann P, Durand A, et al. (1988) Pharmacokinetics and metabolism of zolpidem in various animal species and in humans, in Imidazopyridines in Sleep Disorders (Sauvanet JP, Langer SZ and Morselli PL eds) pp 139-153, Raven Press, New York.
28. Unden M and Roth-Schechter B (1996) Next day effects after nighttime treatment with zolpidem: a review. Eur J Psychiatry 11(Suppl 1):21S-30S.
29. Varhe A, Olkkola KT and Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601-607.
30. Ware JC and Morowitz J (1991) Diagnosis and treatment of insomnia and depression. J Clin Psychiatry 52(Suppl 6):55-61.
31. Wong SH, Dellafera SS, Fernandes R and Kranzler H (1990) Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. J Chromatogr 499:601-608.
32. Wright CE, Lasher-Sisson TA, Steenwyk RC and Swanson CN (1992) A pharmacokinetic evaluation of the combined administration of triazolam and fluoxeline. Pharmacotherapy 12:103-106.